Advanced in Atrial Septal Defect (ASD)

Timo Kahles

Aarau, AG, CH 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Atrial Septal Defect (ASD)
Aarau, AG, CH 
OverviewLocationsClinical Research

Overview

Timo Kahles practices in Aarau, Switzerland. Mr. Kahles is rated as an Advanced expert by MediFind in the treatment of Atrial Septal Defect (ASD). His top areas of expertise are Patent Foramen Ovale, Stroke, Atrial Septal Defect (ASD), Thrombectomy, and Angioplasty.

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Atrial Septal Defect (ASD).

Gender
Male

Locations

Aarau, AG, Switzerland
Other Locations
Basel, BS 4001, Switzerland
Cantonal Hospital St. Gallen, St. Gallen All In Switzerland, Sankt Gallen, SG, Switzerland
Kantonsspital St Gallen, St Gallen
Switzerland
Lugano, TI, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial
Enrollment Status: Recruiting
Publish Date: August 16, 2023
Intervention Type: Drug
Study Drugs: Dabigatran, Apixaban, Edoxaban, Aspirin, Clopidogrel
Study Phase: Phase 3
Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Enrollment Status: Unknown
Publish Date: November 11, 2021
View 1 Less Clinical Trial

55 Total Publications

Trimethylamine N-oxide (TMAO) for risk stratification after acute ischemic stroke: Results from the BIOSIGNAL cohort study.
Trimethylamine N-oxide (TMAO) for risk stratification after acute ischemic stroke: Results from the BIOSIGNAL cohort study.
Journal: European stroke journal
Published: September 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kahles's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile